middle.news
Zelira Therapeutics Secures $1.15M R&D Refund to Fuel Clinical Pipeline
1:32pm on Tuesday 18th of February, 2025 AEDT
•
Biopharmaceutical
Read Story
Zelira Therapeutics Secures $1.15M R&D Refund to Fuel Clinical Pipeline
1:32pm on Tuesday 18th of February, 2025 AEDT
Key Points
Received $1,153,000 R&D Tax Incentive refund
Funds allocated to clinical development and business operations
Focus on advancing HOPE® 1 and ZENIVOL® products
Plans to expand commercialisation in Germany and US markets
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Zelira Therapeutics (ASX:ZLD)
OPEN ARTICLE